That sounds like true freedom, and also like something I wish deeply that I had time and energy to make my daily driver - I’m a purist, but I’m also a pragmatist and i can feel the burnout already.
Respect for using it as a daily driver - even for a personal only machine, that’s a pretty high bar, especially long term.
It does sound horrific, but mostly because it would be poorly executed by many devs.
Well, and the seeming trend towards install commands that look like curl $file.sh | sh
But if they’re not actively encouraging that, I see no issue with a well maintained install tool, created from well maintained toolsets that work on essentially any platform.
I went into a smidge more detail over on my Mastodon last night, but my response is summed up as “WTAF? No! Freeware is an explicit license, as anyone from the BBS days will recall.”
American here - our FEC takes a very dim view of satirical and otherwise non-existent candidates who file the paperwork to run, which makes me curious... If the Count were to win, who would actually take the seat? Have we any idea who is behind the (highly effective) satire, and would they be able to seamlessly serve?
Ironically, there are two newer formulations and the older soon to be authorised generic. My PBM in their infinite wisdom doesn’t want to cover the cheaper one. My doc has yet to get a PA approved for anyone for the newest version, so I’m stuck with the version they foisted upon us as soon as original exclusivity expired “because sodium raises BP,” and the newer one is salts with other metals.
Funny how they didn’t figure that out years ago……
Unfortunately not an option for specialty and niche drugs. Wish it was, I’d rather him get a cut than a certain PBM
I’m mildly curious to see what happens in the next month or two, as I’m about to hit my OOP max. Never ran into that combo of scenarios before.
The one I’m thinking of has a couple months “bridge” program for uninsured/just started new job/etc, but very time limited and an even bigger hassle as they’ll only send out two weeks instead of a month supply with each shipment.
IIRC, if I had insurance and it explicitly excluded the drug, the card would cover it, but it’s been a couple years since I left that job so memory isn’t clear.
None of is trustworthy. Mine is $$$$, and they know damn well insurance won’t pay it all. Of course, if the FDA didn’t require a single source pharmacy to ship it with all the infrastructure that entails, it would help, but only marginally.
Nightmare of a system even for relatively healthy folks. The older I get, the angrier I get because the people who most need the help are the ones either in enough pain they can’t nav the system, or old enough they don’t know where to start
Nobody is buying the med I have in mind out of pocket, in any world. Orphan drug, rare condition, and six figures a year.
Not to suggest your scenario doesn’t happen - it absolutely does. But I’m more curious about why I have to deal with a tiny company when they’re already eating a couple of grand a month on it.
It’s not a physical card always, it behaves like a secondary insurance payor, and if a $5k drug is covered for $2.5k by insurance, the card writes down the difference to $5 (as far as the patient is concerned).
Not unlike goodrx in principle, but specific to a drug.
As long as the reports that the C-suite gets look pretty, that’s all that matters. Have seen that one from both sides.
“I need five developer hours to implement a UI for this manual process that is time sensitive and exposes us to significant risk if we screw it up. Oh, and I’m the only one who knows how to do it in prod, so we have a bus problem.”
“Nah, I want reports…. Wait, why did we write an HO4 policy in Corpus Christie, AFTER the hurricane warning was issued?”
“See above, and prioritise things that matter.”
Underrepresented at best, at worst it’s arguably too easy to forget that Alpine is more than just container images.
Not sure how to solve that problem, it’s my go to for rolling an image but wouldn’t normally make the shortlist for standalone machines. In a prod env, that’s basically Deb, RHEL derivatives, etc. In a personal env for me, Arch derivs tend to win out on non-critical services if only because I invariably learn something useful that I wouldn’t want to learn in prod.